H.R. 383 · 118th Congress · Health
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
What it does
The Congressional Research Service hasn’t published a summary of this bill yet. Summaries usually follow within a few weeks of introduction.
Roll call votes
No recorded roll call votes on this bill. Most bills never get one; many pass by voice vote or unanimous consent, or stay in committee.
Latest action
Jan 27, 2023 · Referred to the Subcommittee on Health.